Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Peroneal Electric Transcutaneous NeuroModulation (eTNM®): A Novel Method for the Treatment of the Overactive Bladder

J. Krhut, L. Peter, M. Rejchrt, M. Slovak, B. Skugarevska, P. Zvara

. 2021 ; 2021 (-) : 4016346. [pub] 20211006

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003494

Overactive bladder syndrome (OAB) is a prevalent medical problem with a significant impact on the quality of life of the affected individuals. Pharmacotherapy is considered the main treatment method, although it is discontinued in a significant proportion of patients due to inefficacy or associated side effects. If pharmacotherapy fails, patients can undergo peripheral neuromodulation of the somatic nerves of the lower limb or sacral neuromodulation; however, neither of these represents an ideal therapeutic tool. The Peroneal electric Transcutaneous NeuroModulation (Peroneal eTNM®), based on the selective stimulation of the peroneal nerve, is the new fully noninvasive neuromodulation method intended to treat OAB. The URIS® neuromodulation system, engineered to provide Peroneal eTNM®, consists of the URIS® device, URIS® active electrodes, and the biofeedback foot sensor (BFS). The unique design of the URIS® device and URIS® active electrodes allows for the use of a low voltage and current during neuromodulation, which significantly reduces the unpleasant sensations. The BFS allows for precise localization of the active electrodes and for continuous adjustment of the voltage and frequency to achieve the optimal therapeutic effect. The URIS® system adopts several principles of telemedicine, which makes it compatible with the US Food and Drug Administration (FDA) and European Union (EU) regulations for home-based use. This article describes both the Peroneal eTNM® method and the URIS® neuromodulation system, including its technical specifications and data from laboratory testing. Preclinical and early clinical data demonstrate the feasibility of this new method for noninvasive OAB treatment and possible implications for clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003494
003      
CZ-PrNML
005      
20220127150151.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2021/4016346 $2 doi
035    __
$a (PubMed)34659685
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Krhut, Jan $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies Medical Faculty, Ostrava University, Ostrava, Czech Republic
245    10
$a Peroneal Electric Transcutaneous NeuroModulation (eTNM®): A Novel Method for the Treatment of the Overactive Bladder / $c J. Krhut, L. Peter, M. Rejchrt, M. Slovak, B. Skugarevska, P. Zvara
520    9_
$a Overactive bladder syndrome (OAB) is a prevalent medical problem with a significant impact on the quality of life of the affected individuals. Pharmacotherapy is considered the main treatment method, although it is discontinued in a significant proportion of patients due to inefficacy or associated side effects. If pharmacotherapy fails, patients can undergo peripheral neuromodulation of the somatic nerves of the lower limb or sacral neuromodulation; however, neither of these represents an ideal therapeutic tool. The Peroneal electric Transcutaneous NeuroModulation (Peroneal eTNM®), based on the selective stimulation of the peroneal nerve, is the new fully noninvasive neuromodulation method intended to treat OAB. The URIS® neuromodulation system, engineered to provide Peroneal eTNM®, consists of the URIS® device, URIS® active electrodes, and the biofeedback foot sensor (BFS). The unique design of the URIS® device and URIS® active electrodes allows for the use of a low voltage and current during neuromodulation, which significantly reduces the unpleasant sensations. The BFS allows for precise localization of the active electrodes and for continuous adjustment of the voltage and frequency to achieve the optimal therapeutic effect. The URIS® system adopts several principles of telemedicine, which makes it compatible with the US Food and Drug Administration (FDA) and European Union (EU) regulations for home-based use. This article describes both the Peroneal eTNM® method and the URIS® neuromodulation system, including its technical specifications and data from laboratory testing. Preclinical and early clinical data demonstrate the feasibility of this new method for noninvasive OAB treatment and possible implications for clinical practice.
650    12
$a elektrostimulační terapie $7 D004599
650    _2
$a elektrody $7 D004566
650    _2
$a lidé $7 D006801
650    _2
$a kvalita života $7 D011788
650    12
$a telemedicína $7 D017216
650    12
$a hyperaktivní močový měchýř $x terapie $7 D053201
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peter, Lukas $u STIMVIA™, Ostrava, Czech Republic $u Department of Chemistry Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Rejchrt, Michal $u Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Slovak, Martin $u STIMVIA™, Ostrava, Czech Republic
700    1_
$a Skugarevska, Barbora $u Department of Urology, University Hospital, Ostrava, Czech Republic $u Department of Surgical Studies Medical Faculty, Ostrava University, Ostrava, Czech Republic
700    1_
$a Zvara, Peter $u Biomedical Laboratory and Research Unit of Urology Department of Clinical Research, University of Southern Denmark, Odense, Denmark $u Department of Urology, Odense University Hospital, Odense, Denmark
773    0_
$w MED00196657 $t Journal of healthcare engineering $x 2040-2309 $g Roč. 2021, č. - (2021), s. 4016346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34659685 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150148 $b ABA008
999    __
$a ok $b bmc $g 1751062 $s 1154643
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 2021 $c - $d 4016346 $e 20211006 $i 2040-2309 $m Journal of healthcare engineering $n J Healthc Eng $x MED00196657
LZP    __
$a Pubmed-20220113
Back

Find record

Citation metrics

Archiving options